|Videos|April 14, 2023
Advances in Locally Advanced BCC Management
Author(s)Neal Bhatia, MD, Aaron S. Farberg, MD
Dr Aaron Farberg discusses the role of cemiplimab in the management of BCC; highlighting the need to increase the engagement of a multidisciplinary team in the use of this treatment.
Advertisement
Episodes in this series
Advertisement
Related to this article
Shannon Trotter, DO, moderated a Dermatology Times Case-Based Roundtable event on how pharmacokinetics, adverse event timing, and trial response criteria should shape hedgehog pathway inhibitor selection in advanced BCC.
Cosibelimab-ipdl is now an NCCN Category 2A option for locally advanced CSCC in patients ineligible for curative surgery or radiation.
Advertisement
Advertisement
Trending on Dermatology Times
1
Clinicians Debate JAK Inhibitor Selection in Alopecia Areata
2
Menopause and the Skin: Recognizing Changes Beyond Aging
3
Social Media Mythbusters: Can Face Taping Really Prevent Wrinkles?
4
Lutikizumab Meets Primary End Point in Phase 3 HS Trial
5